NCI Budget Process?


How is Grant Funding Policy Made?

Jai Sivakumara

Office of Extramural Finance and Information

Analysis (OEFIA)

January 11, 2023



This Presentation's Objectives are to Deliver

- 1. An Overview of the NCI <u>Grants</u> <u>Budget</u> Process
- 2. A summary of our Federal Government's Budget Appropriation 3 Phases
- 3. A simple explanation of the NCI Budget Allocation Steps via an Analogy
- 4. An appreciation of the NCI Budget & Policy: Considerations and Difficulties
- 5. A short list of the Principal Ways in which Grants at NCI are Selected for Funding

OBF does
analysis for the
overall NCI
budget

OEFIA provides
the NCI grants
portion of the
analysis



What is OEFIA's Role?

(Office of Extramural Finance and Information Analysis)

- Fiscal Control of the Grants Budget
- Budget Formulation analyses & projections
- Funding Policy & Budget Analysis to inform NCI Leadership decisions
- SPL Selection meetings organize submissions & manage funds availability
- Monitor Spending throughout the FY to identify and correct potential shortfalls/overages;
 recover all grant balances for EOY close-out
- NIH-required financial reporting
- Ad Hoc Information Requests funding analysis, data studies, Congressional inquiries

Budget Appropriation

Submissions

- Traditional Budget
 - Prepared within NIH and DHHS guidelines
 - Submitted to the President by the Secretary, DHHS
- Annual Plan and Budget Proposal (Bypass Budget)
 - Professional Judgment Budget optimum funding needed to make the most rapid progress against cancer (a "needs" estimate)
 - Required by statute
 - Sent directly to the President & Congress by NCI Director ("bypasses" DHHS, NIH, & Advisory Council)
 - Published for FY2024: https://www.cancer.gov/research/annual-plan

Budget Appropriation Phases - FY2023




Formulation through Execution = approx. 2 ½ years

NIH Office of Budget - Budget Process Calendar: https://officeofbudget.od.nih.gov/pdfs/FY22/cy/Budget Process (Timeline Chart)-2022.pdf




Budget Appropriation

Historical Data



NCI Budget Total Obligations

Grants Percentage of Total FY22 (Est.)




FY22 NCI Total Appropriation: Approx. \$6.9 Billion *Includes Moonshot (Cures) and Excludes Serology*



NCI Budget Grants Obligations

RPG Percentage of Total FY22 (Est.)





Budget Allocation

Common NCI Budget Activity Codes

Research Project Grants						
R01	P01	R03	R21	R37	R33	R56
R00	R50	R35	R15	DP1	DP2	DP5
U01	U19	UM1	UH2	UH3	UG3	etc.

Research Centers	
Cancer Centers	P30
Specialized Programs of Research Excellence (SPORE)	P50
Other P50/P20	P50/P20
Specialized Centers	U54
Planning Grants	P20

Other Research			
Cooperative Clinical Trials (NCTN, NCORP)	U10, UG1		
Cancer Education	R25		
Careers	K's		
Pre-Doc to Post-Doc Transition Award	F99		
Conference	R13, U13		
International Research Training Grants	D43		
Research Resource	R24,U24		

Training	
National Research Service Award	Fs & Ts

NIH Budget Mechanisms: http://grants.nih.gov/grants/funding_program.htm

NCI Budget Allocation Steps

Personal Budget Analogy

(FY22 RPG Est. Actuals for Presentation, Not for Distribution)

BUDGET (Salary)	\$2,822M	100%
SMALL BUSINESS SET ASIDE (Taxes)	-\$151M	5%
NON-COMPETING COMMITMENTS (Mortgage)	-\$2,015M	71%
COMPETING AVAILABILITY	\$656	23%
RFA "RESERVE" (Groceries)	-\$75M	3%
REMAINING FOR R01,P01, etc. (Tuition, Retirement)	\$581M	21%

Excludes Moonshot (Cures) and excludes Serology

Note: Non-competing is over 70% of Budget


Funding Policy Considerations

Each FY, NCI Leadership establishes...

- Budget Sub-Allocations (ex. P01, U01, DOC Discretionary)
- RPG Paylines
- Policy Reductions: Competing & Non-competing



Funding Policy Considerations



Funding Policy Considerations

Higher Policy Reduction

Lower Policy Reduction

Lower Average Cost

Higher Average Cost


Fund More Grants

Fund Fewer Grants





NCI Budget & Policy: Balancing the Various Considerations



The Funding Policy Rubik's Cube



Funding selection possibilities: Paylines, DOC, or SPL

Paylines

- A payline is a percentile or impact score up to which applications will likely be funded with minimal review
- RPGs with paylines R01, R21, R03, R15

DOC Allocations

- Applications outside paylines
- Administrative supplements
- RPG & conference grant allocations
- DOC-controlled budgets



Funding selection possibilities: Paylines, SPL or DOC

Scientific Program Leaders (SPL) selections

- All RFAs
- P01, U01, Large R01 (SPL review for each NCAB Round)
- Other Non-percentiled RPG applications
- Applications outside the paylines
- Research Resource (R24/U24) applications may be submitted for review for each NCAB round

Other SPL Reviews

- RFA Concept Review (for future RFAs)
- DOC-Controlled Funding Plans
- Possible Late/Last List (to expend EOY funds)



Selection Considerations

- Peer review
- Filling gaps in cancer research portfolio
- Especially novel or promising scientific approach
- Commitment to New/Early-Stage Investigators



	Budget Activity/Allocation	Funding Selection Method		
	Research Project Grants (RPGs)			
•	RFAs (various budget activities)	SPL		
	Non-RFAs - (a.k.a Investigator-initiated, PA(R)s, Non-RFAs)			
	R01, R21, R03, R15	Payline		
	P01, U01, Large R01, Other Non-percentiled	SPL		
	DOC RPG Discretionary Allocation (various budget activities)	DOC		
	Research Centers			
	P30, P20, P50, U54	DOC, SPL may review funding plan		
	Other Research			
	R24, U24, D43	SPL		
	R13, U13 (DOC Conference Grant Discretionary Allocation)	DOC		
	U10, UG1 (RFAs)	SPL		
	R25, K's, F99	DOC/Payline, NCI Leadership may review		
	Training			
	Fs, Ts	DOC/Payline		



Funding Approval

View Plan Details for #376

WARNING: Exception Justification has not yet been provided for this plan. You can submit this plan only after providing the required supporting document(s) in Step 5: "Supporting Docs".

Funding Plan Information

→ Hide

Funding Plan Name	FOA	Concept ID	Title	Issue Type
IMAT FY19 Rnd3 R21 Funding	CA18- 002	2602	Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21 - Clinical Trial Not Allowed)	Reissue Previous FOA: CA17- 010
Plan	CA18- 004	2602	Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21 - Clinical Trial Not Allowed)	Reissue Previous FOA: CA17- 012

Fundable Score Range 16 - 27

Applications Received

Applications Proposed for Funding

Applications Skipped

Applications NOT Considered for Funding

Approval Date

Requesting PD

Requesting PD's Cancer Funding Approval Activity

Final Scientific LOA

0

Current Status

80

Other DOC(s) Contributing

SPL Committee Meeting

Dickherber, Anthony J

81

NCI

6


Scientific Program Leaders Committee

Completed - Full Approvals Received

Funds



Funding Approval



OEFIA Web Pages

Office of Extramural Finance and Information Analysis

OEFIA web – main page

https://mynci.cancer.gov/topics/office-extramural-finance-and-information-analysis-oefia

FY23 Funding Information

https://mynci.cancer.gov/topics/oefia-current-fiscal-year-funding-information